IVEH revealed a few more details about their 'revolutionary new product.'
One revealed fact is that the study upon all of this is based was 7 years old, and any rights to products from it were bought for $25,000 three years ago. Company says they were working on getting it into pill form for three years.
CLAREMORE, Okla.--(BW HealthWire)--Feb. 19, 2001--Ives Health Company (OTCBB:IVEH - news):
Public Unveiling of the Java Project Study
Ives Health Company (OTCBB:IVEH - news) announced today that in order to facilitate the public's unbelievable response to T-Factor® and the Java Project, the Company is making a brief summary of the Project, that will include patient profiles, available at iveshealth.com.
The results of this groundbreaking study are now gaining worldwide attention from both the investment and healthcare communities.
Keith Ives, President and Founder of Ives Health Company, stated: ``The sheer amount of excitement surrounding this product has been daunting. When we found the product three years ago, T-Factor® was an unsightly paste that had to be administered through a stomach tube. Thanks to years of dedicated research, we have solved the problems of putting the formula in a pill that is easily swallowed, and preserving that formula until it reaches the consumer. This has required both hard work and vision on the part of our team, our investors, and our clients. We could not be more enthusiastic about helping to improve the lives of hundreds of millions of people who are infected with HIV.''
T-Factor® was released to the public on February 13, 2001, on Ives Health Company's website at iveshealth.com. Mr. Ives continued: ``Because the product has almost no side effects, we are trying to get the word out through HIV and AIDS support groups around the country. We are also attempting to have the product tested and notarized by a celebrity who is battling HIV. HIV is a terrible virus and the enthusiasm that the investment community is showing over T-Factor will help us get the word out to millions of people who desperately need our help.''
About the Java Project and T-Factor®
The Java Project was a landmark AIDS study carried out by Dr. Slayton-Bedeen, an Immunologist and T-Factor® Founder, along with the World Health Organization in Jakarta and Bangkok. The project found that new hormonal inhibitors of the Human Immunodeficiency Virus (HIV), like T-Factor®, might initiate profound and sustained suppression of HIV replication. The T-Factor® formula was administered to 186 HIV-Positive patients of Asian descent with elevated HIV RNA and decreased CD-4 counts, over a period of 24 weeks. The results were dramatic, with over 80% of patients experiencing documented decreases in HIV RNA and enhanced CD-4 counts after 24 weeks.
The T-Factor® formula, acquired by Ives Health Company in 1998, is all-natural, has virtually no side effects, and is readily available over the Internet at iveshealth.com. T-Factor® costs less than $3.00 per day versus $80.00 per day for current HIV drug therapies. New studies are on-going in the United States and recently began in Europe. Findings will be released as the data is reported and validated. T-Factor® is not a cure for HIV, but is intended to extend the lives of those inflicted with the virus. |
